ArticleContemporary oncology (Poznan, Poland)2025
Age and smoking intensity in non-small cell lung cancer patients with the anaplastic lymphoma kinase fusion gene.
Article in Contemporary oncology (Poznan, Poland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Living WithJTO clinical and research reports · 2026Article
- Nanotechnology-Enabled Precision Therapy for Lung Cancer in Never-Smokers.Pharmaceutics · 2026Review
- Cancer-associated thromboses in non-small cell lung cancer patients withContemporary oncology (Poznan, Poland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: It is widely accepted that anaplastic lymphoma kinase (ALK) fusion gene-positive non-small cell lung cancer (NSCLC) patients are more likely to be in their 50s, female, and non-smoking. This seems to be due to the background of patients involved in clinical trials of ALK-tyrosine kinase inhibitors. However, in daily clinical practice, it is not uncommon to encounter elderly ALK-positive NSCLC patients with a smoking history. In light of this background, we conducted a survey to clarify the clinical backgrounds of ALK-positive patients with NSCLC, particularly regarding age and smoking. Material and methods: A retrospective medical chart survey of patients with ALK-positive NSCLC diagnosed in 2012 to 2024 in our six institutes was conducted. Results: During the study period, 140 pa-- tients were diagnosed with ALK-positive NSCLC, of which 90 (64.3%) were women. The median age of all 140 pa-- tients was 63 years (range, 26-84 years). Among these 140 patients, 38.6% had a history of smoking. There was a significant difference in the distribution of smokers by sex and age. Conclusions: Even among NSCLC patients who are elderly or have a history of smoking, there may be some who miss out on the best possible treatment by exclusion from ALK testing. Discussions considering the efficiency and cost of testing are needed, and it is essential to collect and reanalyse as much information as possible about the clinical characteristics of ALK-positive NSCLC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.